Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioceres Crop Solutions (BIOX) Total Non-Current Liabilities (2017 - 2026)

Bioceres Crop Solutions' Total Non-Current Liabilities history spans 10 years, with the latest figure at $136.4 million for Q1 2026.

  • On a quarterly basis, Total Non-Current Liabilities changed N/A to $136.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $136.4 million, a N/A change, with the full-year FY2025 number at $130.4 million, down 24.12% from a year prior.
  • Total Non-Current Liabilities hit $136.4 million in Q1 2026 for Bioceres Crop Solutions, up from $130.4 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for BIOX hit a ceiling of $188.9 million in Q2 2023 and a floor of $130.4 million in Q2 2025.
  • Historically, Total Non-Current Liabilities has averaged $153.0 million across 5 years, with a median of $137.3 million in 2022.
  • Biggest five-year swings in Total Non-Current Liabilities: soared 37.59% in 2023 and later dropped 24.12% in 2025.
  • Tracing BIOX's Total Non-Current Liabilities over 5 years: stood at $137.3 million in 2022, then surged by 37.59% to $188.9 million in 2023, then fell by 9.0% to $171.9 million in 2024, then dropped by 24.12% to $130.4 million in 2025, then grew by 4.6% to $136.4 million in 2026.
  • Business Quant data shows Total Non-Current Liabilities for BIOX at $136.4 million in Q1 2026, $130.4 million in Q2 2025, and $171.9 million in Q2 2024.